Ultra Small Batch Manufacture & R&D from Hosokawa Micron
Hosokawa Micron's new series of Picoline machines, developed for ultra small batch production of one to hundreds of grams of material, offers the widest wet and dry processing options for clinical trials or ultra small scale production available on the market. Meeting the demands of R&D departments, research institutes and those processing expensive materials and active pharmaceutical ingredients this unique equipment for size reduction, mixing, classifying and particle design is developed in miniature from existing and proven Hosokawa Micron technology.
The Picoline range comprises nine individual machines, which can all be fitted into the same compact operating housing. The range includes Picoplex based on the UPZ impact mill, Picozirk an impact classifier mill, Picosplit which is an ultrafine air classifier, Picojet based upon the well know AFG opposed jet mill with integral classifier for ultrafine grinding, Piconizer a spiral jet mill, based on the Alpine AS mill, Picocross a pin mill, Picoliq a wet agitated media mill , largely identical to the AHM mill, Picobond a high energy mixer largely identical to the Nobilta product line and Picomix a high performance batch mixer for dry powders. The flexibility of single housing and easily transposable machines is a major plus point.
Developed from established Hosokawa machines, transfer to volume production is straight forward, reliable and problem free enabling a swift route to market for new products under development. Suitable for bench top or housing in a fume cupboard or compact isolator the units are easy to clean and user friendly. Controlled by means of a touch panel with a microprocessor housed within the platform operating data, settings and system flowcharts etc can be displayed and transmitted to external printers, USB sticks or LMS systems.
A range of accessories for feeding, metering, for example, is also available.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.